Tuesday, 17 September 2024
  
Login

Australia's most trusted
source of pharma news

Tuesday, 17 September 2024
Listen to this story 
News

Drug ready to take PBS throne

Posted 2 May 2024 AM

Keeping true to predictions, MSD's Keytruda is gunning to become the highest earning drug in Australia with a huge surge in sales in the first quarter, being just pipped at the post by Vertex's Trikafta with the difference between first and second place a smidgen over $2 million.

Keytruda was predicted to be the top-selling drug for 2023, but ended up coming second to Trikafta. It was the top-selling drug globally though, and is expected to maintain that position in 2024.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (18)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (5)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.